Efficacy of entecavir combined with compound Biejia Ruangan tablets in the treatment of chronic hepatitis B liver fibrosis

Abstract

Objective To investigate the efficacy of entecavir combined with compound Biejia Ruangan tablets in the treatment of chronic hepatitis B liver fibrosis. Methods 60 patients with chronic hepatitis B liver fibrosis were enrolled in our hospital from April 2015 to March 2018, and were divided into control group and observation group by the random number table, 30 cases in each group. The control group was treated with entecavir, and the observation group was treated with compound Biejia Ruangan tablets on the basis of the control group. HBV DNA negative conversion ratio, the incidence of adverse reactions, liver fibrosis indexes before and after treatment [layer mucin (LN), hyaluronic acid (HA), type III procollagen (PCIII), type IV collagen (IV-C)], liver function indicators [total bilirubin (TBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB)], portal vein blood flow, portal vein diameter, average blood flow velocity, spleen thickness were compared between the two groups. Results After 12 months of treatment, the HBV DNA negative conversion rate of the observation group was 83.33% (25/30), that of the control group was 76.67% (23/30), without statistically significant difference (P>0.05). After 12 months of treatment, the levels of LN, HA, PCIII, and IV-C in the observation group were (135.50±24.41)μg/L, (103.78±17.92)μg/L, (113.49±19.76)μg/L, (171.53±28.41)μg/L, which were lower than those in the control group (P 0.05). Conclusion Entecavir combined with compound Biejia Ruangan tablets is effective in the treatment of liver fibrosis of chronic hepatitis B, which can improve liver function, reduce liver fibrosis, and regulate portal vein blood flow, with high safety. Key words: Chronic hepatitis B; Liver fibrosis; Entecavir; Compound Biejia Ruangan tablet